trending Market Intelligence /marketintelligence/en/news-insights/trending/8AenQJdWOElzBMPEbPHIMg2 content esgSubNav
In This List

Actinium seeks orphan designation from EMA for leukemia drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Actinium seeks orphan designation from EMA for leukemia drug

Actinium Pharmaceuticals Inc. applied for orphan designation with the European Medicines Agency for Actimab-A, a drug for patients with acute myeloid leukemia age 60 and above who are ineligible for currently used induction therapies.

The drug, which already has an orphan designation in the U.S., is currently in phase 2 trial where it is being studied as a monotherapy for patients who have low peripheral blast burden. In its phase 1 trial, Actimab-A showed a 50% composite response rate.